- Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
- Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
More ▼
Key statistics
On Wednesday, Pliant Therapeutics Inc (PLRX:NSQ) closed at 10.58, 2.32% above its 52-week low of 10.34, set on Jun 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.63 |
---|---|
High | 10.70 |
Low | 10.36 |
Bid | 10.30 |
Offer | 12.51 |
Previous close | 10.60 |
Average volume | 758.75k |
---|---|
Shares outstanding | 60.33m |
Free float | 58.61m |
P/E (TTM) | -- |
Market cap | 639.45m USD |
EPS (TTM) | -2.86 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼